Business Wire

CA-MAWI-DNA-TECHNOLOGIES

25.1.2021 15:02:12 CET | Business Wire | Press release

Share
Mawi DNA’s Extractionless Sample Collection Technology Enables BioTech Africa Launch of Affordable COVID-19 Mass Testing Platform

Mawi DNA Technologies’ iSWAB-Microbiome-EL sample collection technology enables BioTech Africa to implement and launch a new ultra-high throughput COVID-19 testing program. This breakthrough, in conjunction with the ProbeSure™ COVID-19 One Step RT-PCR Kit from 3CR Bioscience, is designed to scale up to a capacity of 200,000 tests per day.

“We are extremely proud and humbled to be part of South Africa’s fight against COVID-19 through BioTech Africa’s mass testing efforts,” said Dr. Bassam El-Fahmawi, President and CTO, Mawi DNA Technologies.

In addition, Dr. Jenny Leslie, COO of BioTech Africa, worked closely with Scilutions Labware and Hook Diagnostics to identify the best products and supplier partners who could provide reagents to streamline the testing workflow, but also scale to the projected numbers with minimal supply chain disruption.

“For the sample collection step, Mawi DNA Technologies’ iSWAB-Microbiome-EL (‘Extractionless’) product was chosen for its multiple benefits. This includes enabling direct PCR by removing the RNA extraction step along with extended room temperature stabilization of viral RNA. iSWAB technology also enables simple and efficient non-invasive self-collection, a key component of BioTech Africa’s testing strategy to encourage widespread compliance,” said Dr. Leslie. She added, “When used in tandem with the 3CR Bioscience ProbeSure™ kit, we can provide high throughput testing and faster sample-to-result turnaround time, while significantly reducing reagents, plastics and testing workflow footprint.”

“iSWAB room temperature sample collection and stabilization technology has been well validated in the field with millions of samples tested thus far,” said Dr. Bassam El-Fahmawi. He added that Mawi DNA was pleased to work with Scilutions Labware and Hook Diagnostics to deploy its products on a global scale to help alleviate the socioeconomic impact that COVID-19 brought on the world.

Hook Diagnostics CEO Simon Kratzat added, “Our mission at Hook Diagnostics is to enable affordable population scale testing. We are honored to make this a reality for BioTech Africa together with Mawi DNA, 3CR and Scilutions.”

About Mawi DNA Technologies

Mawi DNA Technologies has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Its flagship product iSWAB-DNA has gained significant market traction due to its ability to be used for animals and all human population segments from infants to the elderly, with robust DNA yield and low bacterial DNA content. iSWAB-Microbiome has gained worldwide acceptance as a superior collection technology for COVID-19 samples. Mawi DNA has expanded its offerings to include collection technologies for intact cells and whole blood. For more information, visit http://www.mawidna.com .

About BioTech Africa

BioTech Africa specializes in recombinant protein production and bioprocessing. Driven by the global requirement for improved in vitro diagnostics, its current range of highly purified recombinant proteins are used in the manufacture of diagnostic test kits for point of care rapid diagnostics and research institutions. BioTech Africa offers a variety of protein expression platforms along with a host of other protein services, including protein refolding and structural biology analysis. For more information, visit http://www.biotechafrica.com .

About Scilutions Labware

Scilutions is an innovative manufacturer of scientific products. Through collaboration with the academic, industrial and scientific communities, its manufacturing capabilities are aligned to ensure that the company is optimized to support critical biomedical operations. For more information, visit http://www.scilutionslabware.com .

About 3CR Bioscience

3CR Bioscience is a world-leading manufacturer of innovative PCR-based reagents. Primary products, PACE™ and ProbeSure™, are used in hundreds of institutions worldwide, from small academic labs to large multinational companies. 3CR has developed the ProbeSure™ COVID-19 One Step RT-PCR Kit which combines high sensitivity and specificity with low cost and has been designed for use in real-time or high-throughput endpoint processes. For more information visit https://3crbio.com/ .

About Hook Diagnostics

Hook Diagnostics is committed to making worldwide population-scale testing faster and more affordable using only the most high quality and cutting edge tools available. For more information, visit http://www.hookdx.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 15:13:00 CEST | Press release

QTSP status allows for full control over the digital trust value chain from identity verification to qualified electronic signature (QES) issuance Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity ve

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release

New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release

By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye